Actavis Inc (ACT) 304.14 $ACT
Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid
at The Street - 27 mins ago
Valeant comes out on top, following a competing bid from Endo International for the gastrointestinal drugmaker Salix.
AGN: 241.07 (+3.73), VRX: 202.07 (+4.64), ACT: 304.14 (+5.19), SHPG: 245.23 (+1.05), PFE: 34.45 (+0.45), SLXP: 172.79 (+3.39), NPSP: 45.97 (+0.01), HSP: 87.65 (+0.09)
Actavis Acquired Allergan: An Upside Potential
Max Grigoryev - at Seeking Alpha - 44 mins ago
ACT: 304.14 (+5.19)
Stocks Near Session Highs; Tesla Up On Musk Tweet
at Investor's Business Daily - 1 hr 19 mins ago
Stocks were holding near session highs going into the noon hour Monday, although volume was tracking lower in the stock market today. Crude oil dropped nearly 4%, bring West Texas Intermediate below 44, its lowest level since late January. Tesla...
AGN: 241.07 (+3.73), NFLX: 420.27 (-18.13), ENDP: 89.37 (+2.04), TSLA: 192.38 (+3.70), ACT: 304.14 (+5.19), VRX: 202.07 (+4.64), SLXP: 172.79 (+3.39), EW: 147.48 (+12.13)
Akorn Fights Off Competitive Drugmakers
Richard Robinson, Ph.D. - at Seeking Alpha - Sun Mar 15, 1:36AM CDT
Prescription drug costs rose 13% in 2014. That's the biggest year-over-year increase since 2003. And the prices of specialty medicines for rare or hard-to-treat conditions jumped by 31%! Now, the higher prices are fueling fierce competition between...
ACT: 304.14 (+5.19), AKRX: 42.58 (+1.30), TEVA: 60.60 (+0.60)
Allergan Cost Synergies On Track For Large Upside
Jehan Ghandhy - at Seeking Alpha - Sat Mar 14, 8:12AM CDT
AGN: 241.07 (+3.73), ACT: 304.14 (+5.19)
3 IBD 50 Stocks That Gained On Big News This Week
at Investor's Business Daily - Sat Mar 14, 7:02AM CDT
This past week, several top-rated IBD 50 stocks saw big gains on notable news. Watch this video for more information. Stocks mentioned include: Valeant Pharmaceuticals (VRX), Salix Pharmaceuticals (SLXP), Allergan (AGN), Actavis (ACT), Ulta Beauty...
AGN: 241.07 (+3.73), ACT: 304.14 (+5.19), VRX: 202.07 (+4.64), DLTR: 83.38 (+1.47), SLXP: 172.79 (+3.39), DG: 75.37 (+1.07), FDO: 79.76 (+0.46), ULTA: 150.54 (+0.44)
Valeant Mulls Higher Salix Bid, But Don't Expect $170
at Investor's Business Daily - Fri Mar 13, 9:00PM CDT
Valeant Pharmaceuticals (VRX) is reportedly mulling a higher bid for Salix Pharmaceuticals (SLXP) even as Valeant investor Bill Ackman said it won't "overpay." Valeant is considering raising its all-cash offer to above $160 a share, according to...
AGN: 241.07 (+3.73), ENDP: 89.37 (+2.04), ACT: 304.14 (+5.19), VRX: 202.07 (+4.64), SLXP: 172.79 (+3.39)
Celgene, Kinder Morgan and Actavis Set to Join the S&P 100; Several Constituent Changes Announced for S&P 500, S&P MidCap 400 and S&P SmallCap 600
PR Newswire - Fri Mar 13, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
KMI: 40.49 (+0.57), BDX: 143.82 (+1.97), AVP: 7.35 (-0.37), ACT: 304.14 (+5.19), TLMR: 15.26 (+0.44), NBR: 11.59 (-0.37), FCX: 17.64 (-0.50), SLG: 128.79 (+1.37), MHFI: 105.60 (+1.31), BWLD: 187.48 (+2.91), CELG: 120.31 (+2.58), NOV: 48.21 (-0.86), EQIX: 236.77 (+6.28), CFN: 60.13 (+0.16), APA: 59.02 (-0.34), HBI: 33.65 (+1.04), DNR: 7.09 (-0.22), HSIC: 139.80 (+3.43), CELGZ: 3.02 (-0.03)
ACADIA Down on Nuplazid NDA Delay and CEO Resignation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 3:25PM CDT
Shares of ACADIA Pharmaceuticals (ACAD) plunged 22.2% after the company announced that its planned NDA on pipeline candidate Nuplazid has been delayed and that its CEO has retired.
MNK: 126.25 (+2.13), IPXL: 45.18 (-0.09), ACT: 304.14 (+5.19), ACAD: 33.90 (-0.55)
Actavis' Generic Pulmicort on Hold until Final Verdict - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 3:20PM CDT
Actavis (ACT) announced that the U.S. Court has granted AstraZeneca's (AZN) request for an injunction pending appeal in relation to Pulmicort.
IPXL: 45.18 (-0.09), ACT: 304.14 (+5.19), AZN: 68.82 (+1.47), TEVA: 60.60 (+0.60)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 304.14 (+5.19), PCYC: 255.79 (+0.81), ITEK: 5.74 (+0.05), REDX: (), PTX: 10.09 (+0.02), CLDX: 30.30 (+0.56), ILMN: 194.45 (+6.24), IDGX: (), ACAD: 33.90 (-0.55), TRGT: 2.64 (unch), EXAC: 24.07 (+0.48), ABBV: 58.94 (+0.94), CRMD: 7.99 (-0.41), AGMX: (), ZGNX: 1.31 (+0.01), VVUS: 2.85 (+0.03), SPPI: 6.16 (-0.08), GSK: 46.90 (+0.53), OREX: 6.93 (-0.11), SQNM: 3.95 (+0.12), IRWD: 15.54 (+0.47), GILD: 101.04 (+1.43), MRK: 57.03 (+0.83), OHRP: 9.46 (-0.25), TEVA: 60.60 (+0.60)
The Zacks Analyst Blog Highlights: NXP Semiconductors, Actavis and Cimpress - Press Releases
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: NXP Semiconductors, Actavis and Cimpress
ACT: 304.14 (+5.19), CMPR: 82.21 (+0.50), NXPI: 103.66 (-1.01)
Actavis Receives FDA Approval of SAPHRIS® for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder
PR Newswire - Fri Mar 13, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for SAPHRIS® (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 - 17). SAPHRIS is the only atypical antipsychotic treatment option with a sublingual (under the tongue) formulation.
ACT: 304.14 (+5.19)
Intravenous (IV) Iron Drugs - 2015 Global Strategic Business Report
M2 - Fri Mar 13, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37664v/intravenous_iv) has announced the addition of the "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 17 companies including many key and niche players such as: - Actavis, Inc. (US) - AMAG Pharmaceuticals, Inc. (US) - Fresenius Medical Care AG & Co. KGaA (Germany) - Galenica Ltd. (Switzerland) - Vifor Pharma Ltd. (Switzerland) - Luitpold Pharmaceuticals, Inc. (US) - American Regent, Inc. (US) - Pharmacosmos A/S (Denmark) - Sanofi US (US) - Takeda Pharmaceutical Company Limited (Japan) Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW & TRENDS 3. REGULATORY OVERVIEW 4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS 5. PRODUCT LAUNCHES/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 17 (including Divisions/Subsidiaries 20) - The United States (6) - Japan (2) - Europe (5) - Germany (1) - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (7) For more information visit http://www.researchandmarkets.com/research/37...avenous_iv
ACT: 304.14 (+5.19), AMAG: 54.58 (-0.42)
Actavis Confirms Appeals Court Grants Injunction Pending Appeal Related to Generic Pulmicort RESPULES®
PR Newswire - Thu Mar 12, 4:00PM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has granted AstraZeneca's request for an injunction pending appeal preventing Actavis from further distribution of its generic version of Pulmicort RESPULES® (budesonide inhalation suspension) 0.25, 0.5 mg.
ACT: 304.14 (+5.19)
Actavis Announces Closing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan
PR Newswire - Thu Mar 12, 3:30PM CDT
Actavis plc (NYSE: ACT) today announced that it has closed an offering of $21 billion aggregate principal amount of senior unsecured notes in 10 tranches in a registered public offering issued by its indirect wholly-owned subsidiary, Actavis Funding SCS, and guaranteed by certain of its other subsidiaries (the "Notes"
, as follows:
AGN: 241.07 (+3.73), ACT: 304.14 (+5.19)
Supernus Gains on Solid Q4 Earnings, Encouraging Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 2:46PM CDT
Shares of Supernus Pharmaceuticals, Inc. (SUPN) gained 10.8% after the company reported solid results for the fourth quarter of 2014.
MNK: 126.25 (+2.13), IPXL: 45.18 (-0.09), ACT: 304.14 (+5.19), SUPN: 11.50 (-0.27)
Stocks Post Nice Gains, But Volume Is Missing
at Investor's Business Daily - Thu Mar 12, 1:57PM CDT
As stocks headed into the final hour of trade Thursday, the indexes held nice gains but with a drawback. Volume was unimpressive, running about even with the previous session. The indexes haven't combined a sizable gain with rising volume yet this...
ACT: 304.14 (+5.19), AXP: 81.31 (+0.71), AKRX: 42.58 (+1.30), ULTA: 150.54 (+0.44)
How To Invest: Several Elements Make Up A Great Base
at Investor's Business Daily - Thu Mar 12, 1:08PM CDT
For nearly three weeks, this space has been dedicated to answering the question: "What makes a great base?" If you're relatively new to IBD, the term base is used a lot. It's an area of price consolidation for a stock. A base forms when a stock takes...
UA: 76.89 (+0.84), ACT: 304.14 (+5.19)
Stocks Hold Strong Gains; JetBlue Leads Airline Rally
at Investor's Business Daily - Thu Mar 12, 12:39PM CDT
Stocks held solid gains in early afternoon trading as weakness in the U.S. dollar kept sellers at bay. Volume was running slightly ahead of Thursday's pace in the stock market today. The Nasdaq rose 0.6%, the S&P 500 1% and the Dow Jones industrial...
NOAH: 21.38 (+0.59), PAYX: 50.66 (+0.74), ACT: 304.14 (+5.19), AKRX: 42.58 (+1.30), MYL: 60.59 (+0.83), JBLU: 18.75 (+0.63), DG: 75.37 (+1.07)
Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid
at The Street - 27 mins ago
Valeant comes out on top, following a competing bid from Endo International for the gastrointestinal drugmaker Salix.
AGN: 241.07 (+3.73), VRX: 202.07 (+4.64), ACT: 304.14 (+5.19), SHPG: 245.23 (+1.05), PFE: 34.45 (+0.45), SLXP: 172.79 (+3.39), NPSP: 45.97 (+0.01), HSP: 87.65 (+0.09)
Actavis Acquired Allergan: An Upside Potential
Max Grigoryev - at Seeking Alpha - 44 mins ago
ACT: 304.14 (+5.19)
Stocks Near Session Highs; Tesla Up On Musk Tweet
at Investor's Business Daily - 1 hr 19 mins ago
Stocks were holding near session highs going into the noon hour Monday, although volume was tracking lower in the stock market today. Crude oil dropped nearly 4%, bring West Texas Intermediate below 44, its lowest level since late January. Tesla...
AGN: 241.07 (+3.73), NFLX: 420.27 (-18.13), ENDP: 89.37 (+2.04), TSLA: 192.38 (+3.70), ACT: 304.14 (+5.19), VRX: 202.07 (+4.64), SLXP: 172.79 (+3.39), EW: 147.48 (+12.13)
Akorn Fights Off Competitive Drugmakers
Richard Robinson, Ph.D. - at Seeking Alpha - Sun Mar 15, 1:36AM CDT
Prescription drug costs rose 13% in 2014. That's the biggest year-over-year increase since 2003. And the prices of specialty medicines for rare or hard-to-treat conditions jumped by 31%! Now, the higher prices are fueling fierce competition between...
ACT: 304.14 (+5.19), AKRX: 42.58 (+1.30), TEVA: 60.60 (+0.60)
Allergan Cost Synergies On Track For Large Upside
Jehan Ghandhy - at Seeking Alpha - Sat Mar 14, 8:12AM CDT
AGN: 241.07 (+3.73), ACT: 304.14 (+5.19)
3 IBD 50 Stocks That Gained On Big News This Week
at Investor's Business Daily - Sat Mar 14, 7:02AM CDT
This past week, several top-rated IBD 50 stocks saw big gains on notable news. Watch this video for more information. Stocks mentioned include: Valeant Pharmaceuticals (VRX), Salix Pharmaceuticals (SLXP), Allergan (AGN), Actavis (ACT), Ulta Beauty...
AGN: 241.07 (+3.73), ACT: 304.14 (+5.19), VRX: 202.07 (+4.64), DLTR: 83.38 (+1.47), SLXP: 172.79 (+3.39), DG: 75.37 (+1.07), FDO: 79.76 (+0.46), ULTA: 150.54 (+0.44)
Valeant Mulls Higher Salix Bid, But Don't Expect $170
at Investor's Business Daily - Fri Mar 13, 9:00PM CDT
Valeant Pharmaceuticals (VRX) is reportedly mulling a higher bid for Salix Pharmaceuticals (SLXP) even as Valeant investor Bill Ackman said it won't "overpay." Valeant is considering raising its all-cash offer to above $160 a share, according to...
AGN: 241.07 (+3.73), ENDP: 89.37 (+2.04), ACT: 304.14 (+5.19), VRX: 202.07 (+4.64), SLXP: 172.79 (+3.39)
Celgene, Kinder Morgan and Actavis Set to Join the S&P 100; Several Constituent Changes Announced for S&P 500, S&P MidCap 400 and S&P SmallCap 600
PR Newswire - Fri Mar 13, 4:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
KMI: 40.49 (+0.57), BDX: 143.82 (+1.97), AVP: 7.35 (-0.37), ACT: 304.14 (+5.19), TLMR: 15.26 (+0.44), NBR: 11.59 (-0.37), FCX: 17.64 (-0.50), SLG: 128.79 (+1.37), MHFI: 105.60 (+1.31), BWLD: 187.48 (+2.91), CELG: 120.31 (+2.58), NOV: 48.21 (-0.86), EQIX: 236.77 (+6.28), CFN: 60.13 (+0.16), APA: 59.02 (-0.34), HBI: 33.65 (+1.04), DNR: 7.09 (-0.22), HSIC: 139.80 (+3.43), CELGZ: 3.02 (-0.03)
ACADIA Down on Nuplazid NDA Delay and CEO Resignation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 3:25PM CDT
Shares of ACADIA Pharmaceuticals (ACAD) plunged 22.2% after the company announced that its planned NDA on pipeline candidate Nuplazid has been delayed and that its CEO has retired.
MNK: 126.25 (+2.13), IPXL: 45.18 (-0.09), ACT: 304.14 (+5.19), ACAD: 33.90 (-0.55)
Actavis' Generic Pulmicort on Hold until Final Verdict - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 3:20PM CDT
Actavis (ACT) announced that the U.S. Court has granted AstraZeneca's (AZN) request for an injunction pending appeal in relation to Pulmicort.
IPXL: 45.18 (-0.09), ACT: 304.14 (+5.19), AZN: 68.82 (+1.47), TEVA: 60.60 (+0.60)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 304.14 (+5.19), PCYC: 255.79 (+0.81), ITEK: 5.74 (+0.05), REDX: (), PTX: 10.09 (+0.02), CLDX: 30.30 (+0.56), ILMN: 194.45 (+6.24), IDGX: (), ACAD: 33.90 (-0.55), TRGT: 2.64 (unch), EXAC: 24.07 (+0.48), ABBV: 58.94 (+0.94), CRMD: 7.99 (-0.41), AGMX: (), ZGNX: 1.31 (+0.01), VVUS: 2.85 (+0.03), SPPI: 6.16 (-0.08), GSK: 46.90 (+0.53), OREX: 6.93 (-0.11), SQNM: 3.95 (+0.12), IRWD: 15.54 (+0.47), GILD: 101.04 (+1.43), MRK: 57.03 (+0.83), OHRP: 9.46 (-0.25), TEVA: 60.60 (+0.60)
The Zacks Analyst Blog Highlights: NXP Semiconductors, Actavis and Cimpress - Press Releases
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: NXP Semiconductors, Actavis and Cimpress
ACT: 304.14 (+5.19), CMPR: 82.21 (+0.50), NXPI: 103.66 (-1.01)
Actavis Receives FDA Approval of SAPHRIS® for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder
PR Newswire - Fri Mar 13, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for SAPHRIS® (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 - 17). SAPHRIS is the only atypical antipsychotic treatment option with a sublingual (under the tongue) formulation.
ACT: 304.14 (+5.19)
Intravenous (IV) Iron Drugs - 2015 Global Strategic Business Report
M2 - Fri Mar 13, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37664v/intravenous_iv) has announced the addition of the "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 17 companies including many key and niche players such as: - Actavis, Inc. (US) - AMAG Pharmaceuticals, Inc. (US) - Fresenius Medical Care AG & Co. KGaA (Germany) - Galenica Ltd. (Switzerland) - Vifor Pharma Ltd. (Switzerland) - Luitpold Pharmaceuticals, Inc. (US) - American Regent, Inc. (US) - Pharmacosmos A/S (Denmark) - Sanofi US (US) - Takeda Pharmaceutical Company Limited (Japan) Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW & TRENDS 3. REGULATORY OVERVIEW 4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS 5. PRODUCT LAUNCHES/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 17 (including Divisions/Subsidiaries 20) - The United States (6) - Japan (2) - Europe (5) - Germany (1) - Rest of Europe (4) - Asia-Pacific (Excluding Japan) (7) For more information visit http://www.researchandmarkets.com/research/37...avenous_iv
ACT: 304.14 (+5.19), AMAG: 54.58 (-0.42)
Actavis Confirms Appeals Court Grants Injunction Pending Appeal Related to Generic Pulmicort RESPULES®
PR Newswire - Thu Mar 12, 4:00PM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has granted AstraZeneca's request for an injunction pending appeal preventing Actavis from further distribution of its generic version of Pulmicort RESPULES® (budesonide inhalation suspension) 0.25, 0.5 mg.
ACT: 304.14 (+5.19)
Actavis Announces Closing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan
PR Newswire - Thu Mar 12, 3:30PM CDT
Actavis plc (NYSE: ACT) today announced that it has closed an offering of $21 billion aggregate principal amount of senior unsecured notes in 10 tranches in a registered public offering issued by its indirect wholly-owned subsidiary, Actavis Funding SCS, and guaranteed by certain of its other subsidiaries (the "Notes"
, as follows: AGN: 241.07 (+3.73), ACT: 304.14 (+5.19)
Supernus Gains on Solid Q4 Earnings, Encouraging Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 2:46PM CDT
Shares of Supernus Pharmaceuticals, Inc. (SUPN) gained 10.8% after the company reported solid results for the fourth quarter of 2014.
MNK: 126.25 (+2.13), IPXL: 45.18 (-0.09), ACT: 304.14 (+5.19), SUPN: 11.50 (-0.27)
Stocks Post Nice Gains, But Volume Is Missing
at Investor's Business Daily - Thu Mar 12, 1:57PM CDT
As stocks headed into the final hour of trade Thursday, the indexes held nice gains but with a drawback. Volume was unimpressive, running about even with the previous session. The indexes haven't combined a sizable gain with rising volume yet this...
ACT: 304.14 (+5.19), AXP: 81.31 (+0.71), AKRX: 42.58 (+1.30), ULTA: 150.54 (+0.44)
How To Invest: Several Elements Make Up A Great Base
at Investor's Business Daily - Thu Mar 12, 1:08PM CDT
For nearly three weeks, this space has been dedicated to answering the question: "What makes a great base?" If you're relatively new to IBD, the term base is used a lot. It's an area of price consolidation for a stock. A base forms when a stock takes...
UA: 76.89 (+0.84), ACT: 304.14 (+5.19)
Stocks Hold Strong Gains; JetBlue Leads Airline Rally
at Investor's Business Daily - Thu Mar 12, 12:39PM CDT
Stocks held solid gains in early afternoon trading as weakness in the U.S. dollar kept sellers at bay. Volume was running slightly ahead of Thursday's pace in the stock market today. The Nasdaq rose 0.6%, the S&P 500 1% and the Dow Jones industrial...
NOAH: 21.38 (+0.59), PAYX: 50.66 (+0.74), ACT: 304.14 (+5.19), AKRX: 42.58 (+1.30), MYL: 60.59 (+0.83), JBLU: 18.75 (+0.63), DG: 75.37 (+1.07)
